U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117890) titled 'Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations' on Aug. 05.
Brief Summary: This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Study Start Date: Feb. 07
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: Sunvozertinib
sunvozertinib 300mg QD
Recruitment Status: RECRUITING
Sponsor: Fudan University
Information provided by (Responsible Party): Jialei Wang, Fudan University
Published by HT Digital Content Services with permission from Health Daily Dig...